RESUMEN
Sheep and goat pox (SGP) with peste des petits ruminants (PPR) are transboundary viral diseases of small ruminants that cause huge economic losses. Recombinant vaccines that can protect from both infections have been reported as a promising solution for the future. SGP was used as a vector to express two structural proteins hemagglutinin or the fusion protein of PPRV. We compared immunity conferred by recombinant capripoxvirus vaccines expressing H or F or both HF. Safety and efficacy were evaluated in goats and sheep. Two vaccine doses were tested in sheep, 104.5TCDI50 in 1ml dose was retained for the further experiment. Results showed that the recombinant HF confers an earlier and stronger immunity against both SGP and PPR. This recombinant vaccine protect also against the disease in exposed and unexposed sheep. The potential Differentiating Infected from Vaccinated Animals of recombinant vaccines is of great advantage in any eradication program.
Asunto(s)
Capripoxvirus/inmunología , Enfermedades de las Cabras/prevención & control , Peste de los Pequeños Rumiantes/virología , Virus de la Peste de los Pequeños Rumiantes/inmunología , Infecciones por Poxviridae/veterinaria , Enfermedades de las Ovejas/prevención & control , Proteínas Virales/inmunología , Vacunas Virales/inmunología , Animales , Anticuerpos Antivirales/inmunología , Capripoxvirus/genética , Capripoxvirus/aislamiento & purificación , Capripoxvirus/fisiología , Enfermedades de las Cabras/inmunología , Enfermedades de las Cabras/virología , Cabras , Hemaglutininas/administración & dosificación , Hemaglutininas/genética , Hemaglutininas/inmunología , Virus de la Peste de los Pequeños Rumiantes/genética , Virus de la Peste de los Pequeños Rumiantes/aislamiento & purificación , Virus de la Peste de los Pequeños Rumiantes/fisiología , Infecciones por Poxviridae/inmunología , Infecciones por Poxviridae/prevención & control , Infecciones por Poxviridae/virología , Ovinos , Enfermedades de las Ovejas/inmunología , Enfermedades de las Ovejas/virología , Proteínas Virales de Fusión/administración & dosificación , Proteínas Virales de Fusión/genética , Proteínas Virales de Fusión/inmunología , Proteínas Virales/administración & dosificación , Proteínas Virales/genética , Vacunas Virales/administración & dosificación , Vacunas Virales/genéticaRESUMEN
AIM: The aim of this study was to determine the prevalence of hepatitis B and the risk factors in Morocco. STUDY DESIGN: A total number of 16,634 individuals were screened for HBsAg using the Murex HBsAg Version 3 assay and were interviewed using a structured standard questionnaire to collect information about risk factor. RESULTS: Two hundred seventy-six subjects were positive for HBsAg, the prevalence of HBV infection was 1.66%. Using a structured standard questionnaire we reported that sexual behaviours (43.84%) are among the main risk factors for HBV transmission. CONCLUSION: This study indicates that the prevalence of HBsAg in Morocco is currently estimated at 1.66% in the active population. The risk factors for HBV infection identified here indicate that prevention is the most cost-effective method for successfully controlling HBV infection, so vaccination remains the best way to control this infection and its related complications.